Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972-2009

Australian and New Zealand Journal of Public Health

Volumn 40, Issue 3, 2016, Pages 255-262

  Soeberg, Matthew J ^a,b   Creighton, Nicola ^c   Currow, David C ^c   Young, Jane M ^a   Van Zandwijk, Nico ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CANCER INSTITUTE NSW   (Australia)

Author keywords

Australia; incidence; malignant mesothelioma; mortality; peritoneal; pleural; relative survival

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; COMBINATION DRUG THERAPY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; INCIDENCE; MALE; MESOTHELIOMA; MIDDLE AGED; MORTALITY; NEW SOUTH WALES; PATHOLOGY; PERITONEAL NEOPLASMS; PLEURAL NEOPLASMS; REGISTER; SEX RATIO; SURVIVAL ANALYSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INCIDENCE; MALE; MESOTHELIOMA; MIDDLE AGED; NEW SOUTH WALES; PERITONEAL NEOPLASMS; PLEURAL NEOPLASMS; REGISTRIES; SEX DISTRIBUTION; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84952837866     PISSN: 13260200     EISSN: 17536405     Source Type: Journal    
DOI: 10.1111/1753-6405.12503     Document Type: Review

References (56)

1. Henderson D, Whitaker D, Shilkin K,. The differential diagnosis of malignant mesothelioma: A practical approach during life. In:, Henderson D, Shilkin K, Langlois S, et al, editors. Malignant Mesothelioma. New York (NY): Hemisphere Publishing; 1992. p. 183-97.
2. Clement PB, Young RH, Scully RE,. Malignant mesotheliomas presenting as ovarian masses. A report of nine cases, including two primary ovarian mesotheliomas. Am J Surg Pathol. 1996; 20: 1067-80.
3. Wolff H, Vehmas T, Oksa P, et al., Asbestos, asbestosis, and cancer, the Helsinki criteria for diagnosis and attribution 2014: Recommendations. Scand J Work Environ Health. 2015; 41: 5-15.
4. Asbestos, asbestosis, and cancer: The Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health. 1997; 23: 311-16.
5. Jamrozik E, de Klerk N, Musk AW,. Asbestos-related disease. Intern Med J. 2011; 41: 372-80.
6. Leigh J, Davidson P, Hendrie L, et al., Malignant mesothelioma in Australia, 1945-2000. Am J Ind Med. 2002; 41: 188-201.
7. Kirby T,. Fears of a new wave of mesothelioma in home renovators? Lancet Respir Med. 2013; 1: 18.
8. Olsen NJ, Franklin PJ, Reid A, et al., Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation. Med J Aust. 2011; 195: 271-4.
9. Park EK, Yates DH, Hyland RA, et al., Asbestos exposure during home renovation in New South Wales. Med J Aust. 2013; 199: 410-13.
10. Forman D, Bray F, Brewster D, et al., Cancer Incidence in Five Continents. Vol X. IARC Scientific Publication, No 164. Lyon (FRA): International Agency for Research on Cancer; 2014.
11. Australian Mesothelioma Registry. 3rd Annual Report Mesothelioma in Australia 2013. Sydney (AUST): Cancer Insitiute New South Wales; 2014.
12. Moolgavkar SH, Meza R, Turim J,. Pleural and peritoneal mesotheliomas in SEER: Age effects and temporal trends, 1973-2005. Cancer Causes Control. 2009; 20: 935-44.
13. Clements M, Berry G, Shi J, et al., Projected mesothelioma incidence in men in New South Wales. Occup Environ Med. 2007; 64: 747-52.
14. Hyland RA, Ware S, Johnson AR, et al., Incidence trends and gender differences in malignant mesothelioma in New South Wales, Australia. Scand J Work Environ Health. 2007; 33: 286-92.
15. Corbett S, Stokes M-L,. Malignant mesothelioma and asbestos exposure in NSW. N S W Public Health Bull. 1994; 5.
16. Kao SC, Clarke S, Vardy J, et al., Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia. Intern Med J. 2013; 43: 402-10.
17. Kao SC, Vardy J, Chatfield M, et al., Validation of prognostic factors in malignant pleural mesothelioma: A retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. Clin Lung Cancer. 2013; 14: 70-7.
18. Linton A, Pavlakis N, O'Connell R, et al., Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer. 2014; 111: 1860-9.
19. Fennell DA, Gaudino G, O'Byrne KJ, et al., Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol. 2008; 5: 136-47.
20. Currow D, Thompson W,. Cancer in NSW: Incidence Report. Sydney (AUST): Cancer Institute New South Wales; 2014.
21. Sitas F, Gibberd A, Kahn C, et al., Cancer incidence and mortality in people aged less than 75 years: changes in Australia over the period 1987-2007. Cancer Epidemiol. 2013; 37: 780-7.
22. Cao C, Yan TD, Bannon PG, et al., Summary of prognostic factors and patient selection for extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma. Ann Surg Oncol. 2011; 18: 2973-9.
23. Meyerhoff RR, Yang CF, Speicher PJ, et al., Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res. 2015; 196 (1): 23-32.
24. Department of Planning and Infrastructure. New South Wales in the Future: Preliminary 2013 Population Projections. Preliminary Release of NSW State and local Government Area Population Projections. Sydney (AUST): State Government of New South Wales; 2013.
25. Australian Bureau of Statistics. 3235.0-Population by Age and Sex, Regions of Australia. Canberra (AUST): ABS; 2013.
26. Brenner H, Arndt V,. Recent increase in cancer survival according to age: Higher survival in all age groups, but widening age gradient. Cancer Causes Control. 2004; 15: 903-10.
27. Brenner H, Gefeller O,. An alternative approach to monitoring cancer patient survival. Cancer. 1996; 78: 2004-10.
28. Ederer F, Axtell LM, Cutler SJ,. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961; 6: 101-21.
29. Dickman PW, Sloggett A, Hills M, et al., Regression models for relative survival. Stat Med. 2004; 23: 51-64.
30. Forman D, Bray F, Brewster D, et al., Cancer Incidence in Five Continents. Vol X. IARC Scientific Publication, No 164. Lyon (FRA): International Agency for Research on Cancer; 2013.
31. Dragon J, Thompson J, MacPherson M, et al., Differential susceptibility of human pleural and peritoneal mesothelial cells to asbestos exposure. J Cell Biochem 2015; 116 (8): 1540-52.
32. Boffetta P,. Epidemiology of peritoneal mesothelioma: A review. Ann Oncol. 2007; 18: 985-90.
33. Cocco P, Dosemeci M,. Peritoneal cancer and occupational exposure to asbestos: Results from the application of a job-exposure matrix. Am J Ind Med. 1999; 35: 9-14.
34. Coggon D, Inskip H, Winter P, et al., Differences in occupational mortality from pleural cancer, peritoneal cancer, and asbestosis. Occup Environ Med. 1995; 52: 775-7.
35. Hodgson JT, Darnton A,. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg. 2000; 44: 565-601.
36. Baris I, Simonato L, Artvinli M, et al., Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: A four-year study in the Cappadocian region of Turkey. Int J Cancer. 1987; 39: 10-17.
37. Baris YI, Saracci R, Simonato L, et al., Malignant mesothelioma and radiological chest abnormalities in two villages in Central Turkey. An epidemiological and environmental investigation. Lancet. 1981; 1: 984-7.
38. Andersson M, Wallin H, Jonsson M, et al., Lung carcinoma and malignant mesothelioma in patients exposed to Thorotrast: Incidence, histology and p53 status. Int J Cancer 1995; 63: 330-6.
39. Shivapurkar N, Wiethege T, Wistuba II, et al., Presence of simian virus 40 sequences in malignant pleural, peritoneal and noninvasive mesotheliomas. Int J Cancer. 2000; 85: 743-5.
40. Peterson JT Jr, Greenberg SD, Buffler PA,. Non-asbestos-related malignant mesothelioma. A review. Cancer. 1984; 54: 951-60.
41. Sugarbaker PH, Acherman YI, Gonzalez-Moreno S, et al., Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience. Semin Oncol. 2002; 29: 51-61.
42. Turner K, Varghese S, Alexander HR Jr,. Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma. J Natl Compr Canc Netw. 2012; 10: 49-57.
43. Nielsen AM, Olsen JH, Madsen PM, et al., Peritoneal mesotheliomas in Danish women: Review of histopathologic slides and history of abdominal surgery. Acta Obstet Gynecol Scand. 1994; 73: 581-5.
44. Macfarlane E, Benke G, Sim MR, et al., OccIDEAS: An innovative tool to assess past asbestos exposure in the Australian Mesothelioma Registry. Saf Health Work. 2012; 3: 71-6.
45. Montanaro F, Bray F, Gennaro V, et al., Pleural mesothelioma incidence in Europe: Evidence of some deceleration in the increasing trends. Cancer Causes Control. 2003; 14: 791-803.
46. Linton A, Vardy J, Clarke S, et al., The ticking time-bomb of asbestos: Its insidious role in the development of malignant mesothelioma. Crit Rev Oncol Hematol. 2012; 84: 200-12.
47. Henderson DW, Reid G, Kao SC, et al., Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. J Clin Pathol. 2013; 66: 854-61.
48. Henderson DW, Reid G, Kao SC, et al., Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol. 2013; 66: 847-53.
49. Hjerpe A, Ascoli V, Bedrossian CW, et al., Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Complementary statement from the international mesothelioma interest group, also endorsed by the international academy of cytology and the papanicolaou society of cytopathology. Acta Cytol. 2015; 59: 2-16.
50. Australian Institute of Health and Welfare. Cancer survival and prevalence in Australia: Period estimates from 1982 to 2010. Asia Pac J Clin Oncol. 2013; 9: 29-39.
51. Thursfield V, Farrugia H, Karahalios E, et al., Cancer in Survival Victoria 2012: Estimates of Survival for 2006-2010 (and Comparisons with Earlier Periods). Melbourne (AUST): Cancer Council Victoria; 2012.
52. Francisci S, Minicozzi P, Pierannunzio D, et al., Survival patterns in lung and pleural cancer in Europe 1999-2007: Results from the EUROCARE-5 study. Eur J Cancer. 2015; 51 (15): 2242-53.
53. Cao C, Krog Andvik SK, Yan TD, et al., Staging of patients after extrapleural pneumonectomy for malignant pleural mesothelioma-institutional review and current update. Interact Cardiovasc Thorac Surg. 2011; 12: 754-7.
54. Damhuis RA, Schroten C, Burgers JA,. Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. Eur Respir J. 2012; 40: 185-9.
55. Antman K, Shemin R, Ryan L, et al., Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol. 1988; 6: 147-53.
56. Musk AW, Olsen N, Alfonso H, et al., Predicting survival in malignant mesothelioma. Eur Respir J. 2011; 38: 1420-4.